• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尼姆斯医院新冠护理设施出院患者的症状患病率:逆转录聚合酶链反应阴性是否真的反映康复?一项单中心观察性研究。

Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study.

作者信息

Tomar Balvir S, Singh Mahaveer, Nathiya Deepak, Sharma Abhishek, Sharma Eshan, Bareth Hemant, Suman Supriya, Ruparelia Darshan Purshotambhai, Patel Jaykumar Bharatbhai, Gajera Vikrant Kantilal

机构信息

Institute of Gastroenterology, Hepatology & Transplant, Nims University Rajasthan, Jaipur, India.

Department of Endocrinology, National Institute of Medical Sciences and Research Hospital, Nims University Rajasthan, Jaipur, 303121, India.

出版信息

Int J Gen Med. 2021 Mar 25;14:1069-1078. doi: 10.2147/IJGM.S295499. eCollection 2021.

DOI:10.2147/IJGM.S295499
PMID:33790636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8006813/
Abstract

PURPOSE

To assess the prevalence of post-COVID symptoms in patients with recovered COVID-19 (nasopharyngeal RT PCR negative) who were discharged from an acute COVID care facility at a tertiary care teaching hospital in North India.

METHODS

This study was an observational study with retrospective data collection, conducted in the COVID follow-up clinic, a combined clinic of medicine and endocrinology. Patients discharged from the acute COVID care facility were recruited after 14 days of discharge if they fulfilled inclusion and exclusion criteria. The retrospective data was collected from the hospital records/EMR and analysed by the SPSSv23.

RESULTS

Fifty patients, who fulfilled the inclusion and exclusion criteria, were included in the study. The Mean age of patients was 53.4±13.8 years (range 28-77). Seventy six percent were male, and 38% had type 2 diabetes. Fever (94%), cough (78%) and breathlessness (68%), were the most common symptoms at presentation to acute care facility. Oxygen saturation at presentation had a negative correlation with D-Dimer, age, and C reactive protein. When patients were evaluated clinically, after 14 days (range 15 to 50 days) of the discharge, 82% of patients had at least one persistent symptom. Fatigue (74%) was the most common symptoms in follow-up followed by breathlessness (44%), and muscle weakness (36%). Two patients had persistent fever, even after negative RT PCR status.

CONCLUSION

Patients discharged from the acute COVID care facility had a high prevalence of post-COVID symptoms even after 14 days.

摘要

目的

评估在印度北部一家三级护理教学医院的急性新冠护理机构出院的新冠康复患者(鼻咽RT-PCR检测阴性)中新冠后症状的患病率。

方法

本研究是一项采用回顾性数据收集的观察性研究,在新冠随访诊所(一个内科和内分泌科联合诊所)进行。从急性新冠护理机构出院的患者在出院14天后,如果符合纳入和排除标准则被招募。回顾性数据从医院记录/电子病历中收集,并通过SPSSv23进行分析。

结果

50名符合纳入和排除标准的患者被纳入研究。患者的平均年龄为53.4±13.8岁(范围28-77岁)。76%为男性,38%患有2型糖尿病。发热(94%)、咳嗽(78%)和呼吸困难(68%)是就诊于急性护理机构时最常见的症状。就诊时的血氧饱和度与D-二聚体、年龄和C反应蛋白呈负相关。当患者在出院14天(范围15至50天)后进行临床评估时,82%的患者至少有一种持续症状。疲劳(74%)是随访中最常见的症状,其次是呼吸困难(44%)和肌肉无力(36%)。两名患者即使RT-PCR检测呈阴性仍持续发热。

结论

即使在出院14天后,从急性新冠护理机构出院的患者中新冠后症状的患病率仍很高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e740/8006813/42ad92bdf4eb/IJGM-14-1069-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e740/8006813/a2cfc8b69254/IJGM-14-1069-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e740/8006813/42ad92bdf4eb/IJGM-14-1069-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e740/8006813/a2cfc8b69254/IJGM-14-1069-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e740/8006813/42ad92bdf4eb/IJGM-14-1069-g0002.jpg

相似文献

1
Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study.尼姆斯医院新冠护理设施出院患者的症状患病率:逆转录聚合酶链反应阴性是否真的反映康复?一项单中心观察性研究。
Int J Gen Med. 2021 Mar 25;14:1069-1078. doi: 10.2147/IJGM.S295499. eCollection 2021.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India.在印度北部的一家三级护理中心住院的 COVID-19 患者的临床人口统计学特征和医院结局。
Indian J Med Res. 2020;152(1 & 2):61-69. doi: 10.4103/ijmr.IJMR_1788_20.
4
A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.一项评价阿司匹林、阿托伐他汀和尼可地尔三联疗法在 SARS-CoV-2 感染住院患者中的疗效和安全性的随机、开放标签试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jul 15;22(1):451. doi: 10.1186/s13063-021-05361-y.
5
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
6
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验(SAINT)评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力:一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
7
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验(SEV-COVID 试验):一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
8
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.随机临床试验比较伊维菌素与安慰剂对秘鲁早期 COVID-19 患者鼻咽 PCR 转阴的疗效(SAINT-Peru):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 9;22(1):262. doi: 10.1186/s13063-021-05236-2.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.用于确定在基层医疗或医院门诊就诊的患者是否患有新冠病毒病的体征和症状。
Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD013665. doi: 10.1002/14651858.CD013665.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗或医院门诊环境中,出现症状和体征来确定患者是否患有 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2.

引用本文的文献

1
Autoantigens of Small Nerve Fibers and Human Coronavirus Antigens: Is There a Possibility for Molecular Mimicry?小纤维神经自身抗原与人类冠状病毒抗原:是否存在分子模拟的可能性?
Curr Microbiol. 2024 Sep 19;81(11):366. doi: 10.1007/s00284-024-03885-5.
2
Characterization of Post-COVID-19 Clinical Manifestations Among Patients Visiting a Post-COVID-19 Clinic in a Tertiary Care Center: A Descriptive Study.三级医疗中心新冠后诊所就诊患者的新冠后临床表现特征:一项描述性研究
Cureus. 2023 Jul 7;15(7):e41523. doi: 10.7759/cureus.41523. eCollection 2023 Jul.
3
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course-A Narrative Review.

本文引用的文献

1
Distinguishable Immunologic Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals.与非糖尿病个体相比,合并 2 型糖尿病的 COVID-19 患者具有明显不同的免疫特征。
Mediators Inflamm. 2020 Sep 29;2020:6914878. doi: 10.1155/2020/6914878. eCollection 2020.
2
Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence.地塞米松用于对抗新冠病毒疾病中的细胞因子风暴:临床试验与初步证据
Int J Surg. 2020 Oct;82:179-181. doi: 10.1016/j.ijsu.2020.08.038. Epub 2020 Sep 4.
3
Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19.
糖尿病和高血糖对新型冠状病毒肺炎感染病程的影响——一篇叙述性综述
Front Clin Diabetes Healthc. 2022 Mar 10;3:812134. doi: 10.3389/fcdhc.2022.812134. eCollection 2022.
4
Global prevalence of chronic fatigue syndrome among long COVID-19 patients: A systematic review and meta-analysis.新冠长期患者中慢性疲劳综合征的全球患病率:一项系统评价和荟萃分析。
Biopsychosoc Med. 2022 Oct 23;16(1):21. doi: 10.1186/s13030-022-00250-5.
5
Risk factors and severity of functional impairment in long COVID: a single-center experience in Croatia.长新冠的风险因素和功能障碍严重程度:克罗地亚单中心经验。
Croat Med J. 2022 Feb 28;63(1):27-35. doi: 10.3325/cmj.2022.27.
6
Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis.血清 C-反应蛋白 (CRP) 和 D-二聚体浓度与 COVID-19 病例严重程度的关联:一项系统评价和荟萃分析。
Expert Rev Endocrinol Metab. 2022 Jan;17(1):83-93. doi: 10.1080/17446651.2022.2002146. Epub 2021 Nov 16.
糖尿病和非糖尿病COVID-19患者凝血功能障碍和炎症的标志物。
J Thromb Thrombolysis. 2021 May;51(4):941-946. doi: 10.1007/s11239-020-02270-w.
4
Anticipating the long-term cardiovascular effects of COVID-19.预测新型冠状病毒肺炎的长期心血管影响。
J Thromb Thrombolysis. 2020 Oct;50(3):512-524. doi: 10.1007/s11239-020-02266-6.
5
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.SARS-CoV-2 与其他冠状病毒与 ACE(血管紧张素转换酶)-2 作为其主要受体的相互作用:治疗意义。
Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27.
6
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
7
Myopathy associated with COVID-19.与新型冠状病毒肺炎相关的肌病
J Formos Med Assoc. 2021 Mar;120(3):1022-1024. doi: 10.1016/j.jfma.2020.07.042. Epub 2020 Aug 3.
8
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.1 型和 2 型糖尿病与英格兰 COVID-19 相关死亡率的关联:一项全人群研究。
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2. Epub 2020 Aug 13.
9
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.英格兰 1 型和 2 型糖尿病患者 COVID-19 相关死亡率的风险因素:一项基于人群的队列研究。
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833. doi: 10.1016/S2213-8587(20)30271-0. Epub 2020 Aug 13.
10
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.补体和组织因子富集的中性粒细胞细胞外陷阱是 COVID-19 免疫血栓形成的关键驱动因素。
J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374.